Asset Allocation

As of December 31, 2025.
Type % Net
Cash 12.93%
Stock 49.27%
Bond 34.30%
Convertible 0.00%
Preferred 0.00%
Other 3.50%
View Asset Allocation
Start Trial

Market Capitalization

Large --
Mid --
Small --
No Data Available
View Market Capitalization
Start Trial

Region Exposure

% Developed Markets: 90.46%    % Emerging Markets: 0.39%    % Unidentified Markets: 9.15%

Americas 86.14%
84.72%
Canada 0.38%
United States 84.35%
1.42%
Mexico 0.10%
As of December 31, 2025. Region breakdown data is calculated by using the long position holdings of the portfolio.
Greater Europe 4.63%
United Kingdom 1.24%
2.07%
Belgium 0.10%
France 0.00%
Greece 0.55%
Ireland 0.63%
Netherlands 0.01%
Sweden 0.00%
Switzerland 0.39%
0.00%
1.32%
Israel 1.32%
Greater Asia 0.07%
Japan 0.00%
0.06%
Australia 0.06%
0.01%
Singapore 0.01%
0.00%
Unidentified Region 9.15%

Bond Credit Quality Exposure

AAA 0.00%
AA 10.34%
A 0.00%
BBB 0.00%
BB 0.00%
B 0.00%
Below B 0.00%
    CCC 0.00%
    CC 0.00%
    C 0.00%
    DDD 0.00%
    DD 0.00%
    D 0.00%
Not Rated 0.00%
Not Available 89.66%
Short Term 0.00%
As of December 31, 2025
View Bond Credit Quality Exposure
Start Trial

Stock Sector Exposure

Cyclical
24.85%
Materials
4.94%
Consumer Discretionary
10.95%
Financials
8.41%
Real Estate
0.55%
Sensitive
36.71%
Communication Services
5.00%
Energy
5.05%
Industrials
10.32%
Information Technology
16.33%
Defensive
14.62%
Consumer Staples
3.51%
Health Care
9.86%
Utilities
1.24%
Not Classified
23.82%
Non Classified Equity
0.18%
Not Classified - Non Equity
23.65%
As of December 31, 2025
View Region Exposure
Start Trial

Bond Sector Exposure

As of December 31, 2025
Type % Net
Government 100.00%
Corporate 0.00%
Securitized 0.00%
Municipal 0.00%
Other 0.00%
View Bond Sector Exposure
Start Trial

Bond Maturity Exposure

Short Term
95.44%
Less than 1 Year
95.44%
Intermediate
4.56%
1 to 3 Years
4.56%
3 to 5 Years
0.00%
5 to 10 Years
0.00%
Long Term
0.00%
10 to 20 Years
0.00%
20 to 30 Years
0.00%
Over 30 Years
0.00%
Other
0.00%
As of December 31, 2025
View Bond Maturity Exposure
Start Trial